Evaluate the long-term safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with pulmonary arterial hypertension (PAH).
ID
Bron
Verkorte titel
Aandoening
Pulmonary arterial hypertension in children
Ondersteuning
Gewerbestrasse 16
CH-4123 Allschwil
Switzerland
Gewerbestrasse 16
CH-4123 Allschwil
Switzerland
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
No primary endpoint was defined in this study.
Achtergrond van het onderzoek
This is a prospective, multicenter, multinational, open-label, double-arm exploratory Phase 3 extension study enrolling those patients who completed the FUTURE 3 core study (AC 052-373). It is designed to evaluate the long-term tolerability and safety of bosentan using the pediatric formulation in children with idiopathic or heritable PAH or PAH persisting after complete repair of a congenital heart defect.
Patients will receive the bosentan pediatric formulation. The bosentan dosage will be adjusted to the patient’s body weight during the study to achieve a maintenance dose of 2 mg/kg either b.i.d. or t.i.d.
The maximum number of participants corresponds to the number of patients treated in the FUTURE 3 core study (AC-052-373).
The study will be conducted at expert pediatric PAH centers in Europe, US, Latin America, Australia and Asia.
The study will consist of a treatment period and a post-treatment follow-up period of 60 days. Patients will receive the maintenance dose (2 mg/kg either b.i.d. or t.i.d.) of bosentan using the pediatric formulation for the entire duration of the study.
The treatment period in FUTURE 3 Study Extension will last for 12 months or until:
1. The investigator or the patient decides to discontinue the study treatment permanently;
2. The sponsor decides not to pursue the development of the pediatric formulation of bosentan.
Doel van het onderzoek
Evaluate the long-term safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with pulmonary arterial hypertension (PAH).
Onderzoeksopzet
The study will consist of a treatment period and a post-treatment follow-up period of 60 days. Patients will receive the maintenance dose (2 mg/kg either b.i.d. or t.i.d.) of bosentan using the pediatric formulation for the entire duration of the study. The treatment period in FUTURE 3 Study Extension will last for 12 months or until:
1. The investigator or the patient decides to discontinue the study treatment permanently;
2. The sponsor decides not to pursue the development of the pediatric formulation of bosentan.
Onderzoeksproduct en/of interventie
Bosentan dispersible tablet (32 mg) in the dosage of 2 mg/kg b.i.d. or 2 mg/kg t.i.d.
Publiek
Peter Westerveld
Woerden 3446 GR
The Netherlands
+31 (0)348 489181
peter.westerveld@actelion.com
Wetenschappelijk
Peter Westerveld
Woerden 3446 GR
The Netherlands
+31 (0)348 489181
peter.westerveld@actelion.com
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Patients who completed the FUTURE 3 core study (AC-052-373) or prematurely discontinued due to PAH progression, if bosentan was not permanently discontinued;
2. Patients who tolerated bosentan pediatric formulation and for whom bosentan is considered beneficial by the investigator at the end of FUTURE 3 core study (AC-052-373);
3. Signed informed consent by the parents or the legal representatives prior to any study-mandated procedure.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Known intolerance or hypersensitivity to bosentan or any of the excipients of the dispersible bosentan tablet;
2. Any clinically significant laboratory abnormality that precludes continuation of bosentan therapy;
3. Pregnancy;
4. AST and/or ALT values > 3 times the upper limit of normal range (ULN);
5. Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C;
6. Premature and permanent study drug discontinuation during the FUTURE 3 core study (AC-052-373);
7. Any major violation of the FUTURE 3 core study (AC 052 373) protocol.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL2538 |
| NTR-old | NTR2656 |
| Ander register | : |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |